Why Idera Pharmaceuticals Soared 20% In September

What:• The clinical-stage biotech company is studying two drugs.– IMO 8400 for B-cell lymphomas.– IMO 9200 for autoimmune disease.

• Data should be released on IMO 8400 in Q4.– Results from its phase 2 Waldenstrom’s

macroglobulinemia trial.• Shares jumped 20.1% in September.

Idera Pharmaceuticals

So what:• Under development to treat Waldenstrom’s and diffuse

B-cell lymphoma with an amenable genetic mutation.– Could benefit up to 90% of 1,200 new WM cases

annually.– Could treat up to 30% of the 2,000 new diffuse B-cell

lymphoma cases annually.

Now what:

• WM phase 2 data coming this quarter.– Mid stage results could be encouraging, but a phase 3

trial still needs to occur.• Diffuse B-cell lymphoma data expected next year.– Potential therapy for pre-treated patients would be

welcome, but too early to gauge whether this one will be a success.

Now what continued:

• Cash totals $106.3 million exiting Q2.– Operating expenses totaled $12.8 million last quarter.– Expanding trials will increase cash burn in the coming

year.• High-risk/high-reward play suitable only for aggressive

investors.– Keep an eye out for upcoming WM data.

Leaked: The next billion-dollar iSecret